Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder

Boadie W. Dunlop, Philip E. Polychroniou, Jeffrey J. Rakofsky, Charles Nemeroff, W. Edward Craighead, Helen S. Mayberg

Research output: Contribution to journalArticle

Abstract

BackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n = 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%; p =.001). Among patients who terminated the trial early (n = 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.

Original languageEnglish (US)
JournalPsychological Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Suicidal Ideation
Major Depressive Disorder
Cognitive Therapy
Antidepressive Agents
Depression
Therapeutics
Recurrence

Keywords

  • Cognitive therapy
  • duloxetine
  • escitalopram
  • Key words
  • prediction
  • SSRI

ASJC Scopus subject areas

  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. / Dunlop, Boadie W.; Polychroniou, Philip E.; Rakofsky, Jeffrey J.; Nemeroff, Charles; Craighead, W. Edward; Mayberg, Helen S.

In: Psychological Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Dunlop, Boadie W. ; Polychroniou, Philip E. ; Rakofsky, Jeffrey J. ; Nemeroff, Charles ; Craighead, W. Edward ; Mayberg, Helen S. / Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. In: Psychological Medicine. 2018.
@article{e81cd2eae5694cff889bf6d98efaa5d8,
title = "Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder",
abstract = "BackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n = 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0{\%}, non-responders to CBT: 8/30, 26.7{\%}; p =.001). Among patients who terminated the trial early (n = 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.",
keywords = "Cognitive therapy, duloxetine, escitalopram, Key words, prediction, SSRI",
author = "Dunlop, {Boadie W.} and Polychroniou, {Philip E.} and Rakofsky, {Jeffrey J.} and Charles Nemeroff and Craighead, {W. Edward} and Mayberg, {Helen S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1017/S0033291718002568",
language = "English (US)",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder

AU - Dunlop, Boadie W.

AU - Polychroniou, Philip E.

AU - Rakofsky, Jeffrey J.

AU - Nemeroff, Charles

AU - Craighead, W. Edward

AU - Mayberg, Helen S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n = 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%; p =.001). Among patients who terminated the trial early (n = 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.

AB - BackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n = 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%; p =.001). Among patients who terminated the trial early (n = 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.

KW - Cognitive therapy

KW - duloxetine

KW - escitalopram

KW - Key words

KW - prediction

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=85053181212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053181212&partnerID=8YFLogxK

U2 - 10.1017/S0033291718002568

DO - 10.1017/S0033291718002568

M3 - Article

JO - Psychological Medicine

JF - Psychological Medicine

SN - 0033-2917

ER -